Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide capable of regulating energy metabolism and application of polypeptide

A technology of energy metabolism and peptides, which is applied in the field of biomedicine to achieve the effect of reducing costs

Active Publication Date: 2017-08-04
深圳中科新进生物科技有限公司
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the drugs and methods currently used to treat obesity and the diseases it causes, including non-alcoholic fatty liver, have certain deficiencies, so it is still necessary to develop more effective and low-side-effect drugs for the treatment of obesity and non-alcoholic fatty liver and method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide capable of regulating energy metabolism and application of polypeptide
  • Polypeptide capable of regulating energy metabolism and application of polypeptide
  • Polypeptide capable of regulating energy metabolism and application of polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] ISAPs 1 functional study of

[0096] 1. Establish obesity and non-alcoholic fatty liver models with high-fat feeding

[0097] Healthy 6-week-old male C57BL / 6SPF mice were purchased from Guangdong Experimental Animal Center, weighing 18-22 g. They were divided into two groups and raised in the SPF grade animal room of Shenzhen Advanced Research Institute. Control group: mice were given normal diet (ND) (normal diet: fat, 5%; carbohydrates, 53%; protein, 23%; total calories 25J / g), free to eat and drink, and fed for 12 weeks. Experimental group: mice were given high-fat diet (HFD) (high-fat diet D12451, Research Diets, Inc.), free to eat and drink, and fed for 12 weeks. Detect its physiological indicators. The mice fed with high-fat diet weigh more than 40g, and the obesity and non-alcoholic fatty liver model (DIO-NAFLD) is considered to be successfully constructed. For comparison of the body weight of mice under construction with those of the control group, see fig...

Embodiment 2

[0121] ISAPs 2 functional study of

[0122] 1. ISAPs 2 Binding to human GPRC6A

[0123] 1.1 Overexpression of hGPRC6A in Hela cells

[0124] 1) Cell plating: Hela cell suspension was mixed with 1.6×10 5 / mL density plated in 6-well plates with 2 mL DMEM per well, at 37 °C, 5% CO 2 Incubate for 24 hours.

[0125] 2) Using Lipofectamine2000 (Invitrogen), the hGPRC6 overexpression vector (pReceiver-M61) was transfected into Hela cells according to the manufacturer's instructions, and the normal medium was replaced 4 hours after transfection.

[0126] 3) 48 hours after transfection, discard the medium, wash the cells at the bottom of the plate twice with sterile PBS, add 300 μL of Trizol solution, extract cellular RNA according to the instructions of RNAiso Plus (TaKaRa), after DNase treatment, use SuperScript T (Invitrogen, Canada) kit was reverse transcribed into cDNA by DNAEngine. Using cDNA as a template, the fluorescent PCR products at each time point were monitored an...

Embodiment 3

[0135] ISAPs 3 functional study of

[0136] 1. Administration of ISAP by intragastric administration 3 Effects on HFD mice

[0137] 6-week-old male wild-type C57BL / 6 mice were used and divided into 6 groups, 6 mice in each group. The first group was given normal diet (ND), the second to sixth groups were given high-fat diet (HFD), and the second group was used as a control , the 3rd to 6th groups were the experimental groups, and they were given 2pmol / g body weight of OCN and ISAP by stomach, respectively, every day. 1 , ISAP 2 , ISAP 3 , for seven weeks, with weekly weight monitoring. See the experimental results Figure 7 A, It can be clearly seen from the figure that, compared with the HFD control group, ISAP 3 group showed significant weight loss.

[0138] Collect the feces of the mice in the 7th week, bake them at 60°C for 3 days, make sure they are dry, then take 1 mg, soak them in a 2:1 mixed solution of 1 ml of chloroform and methanol, then crush the feces with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a polypeptide capable of regulating energy metabolism and application of the polypeptide in preparation of medicines for treating diseases related to disorder of energy metabolism (particularly fat metabolism). The polypeptide disclosed by the invention can achieve the effects of reducing fat absorption, lowering fat accumulation in the liver and regulating the fat metabolism; and compared with a general polypeptide product, the polypeptide disclosed by the invention has the advantage of being orally applied. Therefore, the polypeptide can serve as an active ingredient of a health care product used for regulating the fat metabolism.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a polypeptide regulating energy metabolism and its use in the preparation of medicines for treating diseases related to abnormal energy metabolism, especially abnormal fat metabolism. Background technique [0002] Obesity is a major and growing health problem worldwide. Obesity is also a risk factor for many common diseases (such as atherosclerosis, hypertension, type II diabetes, dyslipidemia, coronary heart disease, osteoarthritis and various malignant tumors). It can also cause more serious problems by reducing exercise capacity and quality of life. The incidence of obesity and diseases caused by obesity are increasing in all developed countries. [0003] Fatty liver is a disease caused by excessive accumulation of fat in liver cells. There are many causes of fatty liver, such as alcoholism, unreasonable diet, sedentary and so on. Its incidence is increasing day by day in Chin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47C12N15/12A61K38/17A61P3/00A61P3/04A61P3/06A61P3/10A61P1/16A61P9/10
CPCA61K38/00C07K14/4728
Inventor 任培根张键滕斌李健姚振宇
Owner 深圳中科新进生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com